A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

BiondVax Pharmaceuticals

Status and phase: Completed; Phase 2; Phase 1

Conditions: Influenza

Treatments: Biological: Multimeric-001 250 mcg; Biological: Multimeric-001 500 mcg; Biological: Adjuvanted Multimeric-001 500mcg; Biological: TIV; Biological: Adjuvant: Montonide isa 51 VG; Biological: Placebo; Biological: Adjuvanted Multimeric-001 250mcg

Study type: Interventional

Funder types: Industry

Identifiers

NCT01010737

BVX-003

Details and patient eligibility

About

This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.

Full description

This is a Phase I/II single-center, randomized, placebo-controlled, single-blind, dose-escalation, double-dose administration study comprising two dosing cohorts (Cohort 1: 250 mcg M-001 per injection and Cohort 2: 500 mcg M-001 per injection) with 20 subjects in each cohort receiving either adjuvanted or non-adjuvanted formulations. The adjuvant used was Montanide ISA VG51. Cohort 3 with 20 subjects was administered placebo. After priming with M-001 or placebo, all participants were administered a boost of a conventional trivalent vaccine on day 42.

There was a minimum of 10 days interval between last dosing of the first injection to the last subject of the 250 μg cohort (Cohort 1) and first dosing of the first subject injection with 500 µg cohort (Cohort 2).

For each subject, the second injection was performed 21+2 days after his/her first injection, provided they were deemed fit to be dosed by a study physician.

The DSMB reviewed the safety data obtained from cohorts 1 and 2 before approving their second injection and before dose escalation.

Enrollment: 60 patients

Sex: All

Ages: 55 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males and females between the age of 55 and 75 years (inclusive):

  • Healthy or treated for any or all of the following conditions:

    • Hypertension, under control with standard medications
    • Hyperlipidemia, medically treated

• Subjects who provide written informed consent to participate in the study.

• Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.

• Haematology, chemistry and urinalysis values with no clinical significance or do not reflect a medical condition which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.

• Female of childbearing age must agree to use an acceptable method of contraception and male subjects should use a condom throughout the study period (including the follow up- where applicable) if female partner is not using an effective contraceptive method.

Exclusion criteria

• Known history of significant medical disorder, which in the investigator's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.
• Renal dysfunction.
• COPD.
• Chronic cardiovascular system disorders (except hypertension adequately controlled by standard medications).
• Asthma
• Diabetes mellitus.
• Subjects with known Guillain Barré Syndrome in the past.
• Two or more hospitalizations within the last year prior to screening visit.
• Bleeding disorders including hemophilia or thrombocytopenia, or treatment with anticoagulant therapy (risk of bleeding with intramuscular injection).
• Immunocompromised patients and those receiving concomitant immunosuppressive therapy; or other immune modulating drugs including chronic steroid treatment.
• Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within eight months prior to the screening visit.
• Administration of any vaccine 30 days before the screening visit.
• Known hypersensitivity to previous influenza vaccination.
• Use of an influenza antiviral medication within 4 weeks of vaccination.
• Known hypersensitivity and/or allergy to any drug or vaccine.
• Known hypersensitivity to egg proteins (eggs or egg products), chicken proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9,
• Known history of drug or alcohol abuse.
• Any clinically significant abnormality upon physical examination or in the clinical laboratory tests at screening visit which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.
• Increased liver enzymes more than 2.5 times above the upper reference level.
• Positive serology for HIV, HCV antibody or HBsAg.
• Any acute medical situation (e.g. acute infection, ongoing flu symptoms) with or without fever within 48 hours of vaccination, which is considered of significance by the Principal Investigator.
• Pregnant or lactating women at entry to study and those who are unwilling to agree to continue to use acceptable methods of contraception for two months after completion of the study (if applicable).
• Positive blood pregnancy test on screening.
• Subjects who participated in another clinical study within 30 days prior to study entry.
• Subjects who are non-cooperative or unwilling to sign consent form.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 6 patient groups

Multimeric-001 250 mcg

Experimental group

Description:

250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.

Treatment:

Biological: Multimeric-001 250 mcg

Biological: TIV

Adjuvant: Montonide isa 51 VG

Active Comparator group

Description:

Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.

Treatment:

Biological: TIV

Biological: Adjuvant: Montonide isa 51 VG

Placebo

Active Comparator group

Description:

PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.

Treatment:

Biological: TIV

Biological: Adjuvant: Montonide isa 51 VG

Multimeric-001 500 mcg

Experimental group

Description:

500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.

Treatment:

Biological: TIV

Biological: Adjuvanted Multimeric-001 500mcg

Adjuvanted Multimeric-001 500mcg

Experimental group

Description:

5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.

Treatment:

Biological: Adjuvanted Multimeric-001 250mcg

Biological: TIV

Adjuvanted Multimeric-001 250mcg

Experimental group

Description:

250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.

Treatment:

Biological: Placebo

Biological: Multimeric-001 500 mcg

Biological: TIV